Effectiveness of an intelligent endoscopic assistant device for detecting gastric neoplasms and its application conditions: a multi-center, randomized, controlled trial

<h2>Abstract</h2> Evidence about the effect of AI systems on upper endoscopy in multi-center, randomized controlled trials is lacking. We aimed to explore whether AI can enhance gastric neoplasm detection and how AI can be applied better in real clinics. Patients from 24 hospitals were allocated to receive AI-assisted esophagogastroduodenoscopy (EGD) or non-assisted EGD from December 21, 2021, to November 11, 2023 (pre-registered, ChiCTR2100054449). Primary outcome was detection rate of gastric neoplasms. Secondary outcomes included detection rate of early gastric cancer and precancerous conditions, biopsy rate, number of blind spots, and procedure/inspection time. We did modified intention-to-treat (m-ITT), per-protocol (PP) analysis, and an exploratory subgroup analysis. A total of 30,540 patients were enrolled. In m-ITT cohort, the detection rate of gastric neoplasms under assistance was higher (RR 1·13, 1·00-1·28; 4·00 vs. 3·52%, p=0·04) with consistent results in the PP cohort. While after a pre-specified pathology review, numerically more gastric neoplasms were detected (RR 1·12, 0·92-1·38; 1·41 vs. 1·26%, p=0·28) with no statistical significance, and the result in PP analysis was consistent. Moreover, the system reduced the number of blind spots from 2·52 to 1·07 and increased the procedure/inspection time significantly. In exploratory subgroup analysis, potential benefits of AI in less experienced endoscopists and fatigue periods were detected. In the experimental group, the AI diagnosed the gastric adenocarcinoma with a sensitivity of 100%. In conclusion, the ENDOANGEL-GC reliably contributed to the homogenization and standardization of endoscopic quality. The detection of gastric neoplasms was numerically improved without statistical significance. Our exploratory analysis seeking the optimal application condition of ENDOANGEL-GC found that AI might play a promising role among less experienced endoscopists and in labor-intensive areas, provides preliminary evidence for future researches.

Authors

Institutions

Publication Details

Journal
The Lancet Regional Health - Western Pacific
Published
2025-02-01
DOI
https://doi.org/10.1016/j.lanwpc.2024.101308
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of an intelligent endoscopic assistant device for detecting gastric neoplasms and its application conditions: a multi-center, randomized, controlled trial

Lilei Yu, Ting Yang, Lianlian Wu, Sean Tan et al.
The Lancet Regional Health - Western Pacific
Gastric Cancer Management and Outcomes
article

Effectiveness of an intelligent endoscopic assistant device for detecting gastric neoplasms and its application conditions: a multi-center, randomized, controlled trial

Lilei Yu, Ting Yang, Lianlian Wu, Sean Tan, Jiamin Wang, Honggang Yu, Yijie Zhu, Xiaoquan Zeng, Mei Deng, Junxiao Wang, Zehua Dong, Xiao Tao, Hongliu Du
article en

Abstract

<h2>Abstract</h2> Evidence about the effect of AI systems on upper endoscopy in multi-center, randomized controlled trials is lacking. We aimed to explore whether AI can enhance gastric neoplasm detection and how AI can be applied better in real clinics. Patients from 24 hospitals were allocated to receive AI-assisted esophagogastroduodenoscopy (EGD) or non-assisted EGD from December 21, 2021, to November 11, 2023 (pre-registered, ChiCTR2100054449). Primary outcome was detection rate of gastric neoplasms. Secondary outcomes included detection rate of early gastric cancer and precancerous conditions, biopsy rate, number of blind spots, and procedure/inspection time. We did modified intention-to-treat (m-ITT), per-protocol (PP) analysis, and an exploratory subgroup analysis. A total of 30,540 patients were enrolled. In m-ITT cohort, the detection rate of gastric neoplasms under assistance was higher (RR 1·13, 1·00-1·28; 4·00 vs. 3·52%, p=0·04) with consistent results in the PP cohort. While after a pre-specified pathology review, numerically more gastric neoplasms were detected (RR 1·12, 0·92-1·38; 1·41 vs. 1·26%, p=0·28) with no statistical significance, and the result in PP analysis was consistent. Moreover, the system reduced the number of blind spots from 2·52 to 1·07 and increased the procedure/inspection time significantly. In exploratory subgroup analysis, potential benefits of AI in less experienced endoscopists and fatigue periods were detected. In the experimental group, the AI diagnosed the gastric adenocarcinoma with a sensitivity of 100%. In conclusion, the ENDOANGEL-GC reliably contributed to the homogenization and standardization of endoscopic quality. The detection of gastric neoplasms was numerically improved without statistical significance. Our exploratory analysis seeking the optimal application condition of ENDOANGEL-GC found that AI might play a promising role among less experienced endoscopists and in labor-intensive areas, provides preliminary evidence for future researches.

The Lancet Regional Health - Western PacificVol. 55
Kunming University of Science and Technology (CN), Wuhan University (CN), First People's Hospital of Yunnan Province (CN), Renmin Hospital of Wuhan University (CN)
Good health and well-being
Openalex Percentile: Top 96%
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.